Increased spine bone density in patients with chronic hepatitis B switched to tenofovir alafenamide: A prospective, multinational study. Alimentary pharmacology & therapeutics Ogawa, E., Jun, D. W., Toyoda, H., Hsu, Y. C., Yoon, E. L., Ahn, S. B., Yeh, M. L., Do, S., Trinh, H. N., Takahashi, H., Enomoto, M., Kawada, N., Yasuda, S., Tseng, C. H., Kawashima, K., Lee, H. A., Inoue, K., Haga, H., Do, A. T., Maeda, M., Hoang, J. H., Cheung, R., Ueno, Y., Eguchi, Y., Furusyo, N., Yu, M. L., Tanaka, Y., Nguyen, M. H. 2023


Data on patients switched to tenofovir alafenamide (TAF) from nucleos(t)ide analogues (NUCs) other than tenofovir disoproxil fumarate are limited.To assess the treatment and renal/bone safety outcomes following the switch to TAF.We prospectively enrolled adult patients with chronic hepatitis B (CHB) who switched from any NUC to TAF at 14 centres in Japan, Korea, Taiwan and the U.S. Study outcomes were viral suppression (VR; HBV DNA?

View details for DOI 10.1111/apt.17785

View details for PubMedID 37882252